Galectin Therapeutics (GALT) Free Cash Flow (2010 - 2026)
Galectin Therapeutics' quarterly Free Cash Flow came in at -$3.9 million in Q1 2026, up 49.79% year-on-year from -$2.6 million in Q1 2025, and up 36.62% quarter-over-quarter from -$6.1 million in Q4 2025.
Galectin Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at -$3.9 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 49.79% year-over-year to -$3.9 million; the trailing twelve-month figure through Mar 2026 stood at -$20.1 million (up 46.3% YoY), and the FY2025 full-year result was -$23.9 million, up 42.78% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$3.9 million, up from -$6.1 million in the prior quarter.
- The five-year high for Free Cash Flow was -$3.5 million in Q3 2025, with the low at -$12.8 million in Q4 2024.
- Average Free Cash Flow over 5 years is -$7.9 million, with a median of -$7.7 million recorded in 2025.
- Year-over-year, Free Cash Flow sank 170.02% in 2024 and soared 59.19% in 2025.
- Tracing GALT's Free Cash Flow over 5 years: stood at -$7.2 million in 2022, then soared by 34.56% to -$4.7 million in 2023, then slumped by 170.02% to -$12.8 million in 2024, then soared by 52.31% to -$6.1 million in 2025, then jumped by 36.62% to -$3.9 million in 2026.
- The last three Free Cash Flow figures came in at -$3.9 million (Q1 2026), -$6.1 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -3.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.87 Mn |
| Mar 31, 2026 | -3.87 Mn |
| Dec 31, 2025 | -6.10 Mn |
| Dec 31, 2025 | -6.10 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Jun 30, 2025 | -6.61 Mn |
| Jun 30, 2025 | -6.61 Mn |
| Mar 31, 2025 | -7.69 Mn |
| Mar 31, 2025 | -7.69 Mn |
| Dec 31, 2024 | -12.77 Mn |
| Dec 31, 2024 | -12.77 Mn |
| Sep 30, 2024 | -8.56 Mn |
| Sep 30, 2024 | -8.56 Mn |
| Jun 30, 2024 | -8.33 Mn |
| Jun 30, 2024 | -8.33 Mn |
| Mar 31, 2024 | -12.11 Mn |
| Mar 31, 2024 | -12.11 Mn |
| Dec 31, 2023 | -4.74 Mn |
| Dec 31, 2023 | -4.74 Mn |
| Sep 30, 2023 | -7.64 Mn |
| Sep 30, 2023 | -7.64 Mn |
| Jun 30, 2023 | -9.83 Mn |
| Jun 30, 2023 | -9.83 Mn |
| Mar 31, 2023 | -10.79 Mn |
| Mar 31, 2023 | -10.79 Mn |
| Dec 31, 2022 | -7.24 Mn |
| Dec 31, 2022 | -7.24 Mn |
| Sep 30, 2022 | -8.35 Mn |
| Sep 30, 2022 | -8.35 Mn |
| Jun 30, 2022 | -7.43 Mn |
| Jun 30, 2022 | -7.43 Mn |
| Mar 31, 2022 | -8.04 Mn |
| Mar 31, 2022 | -8.04 Mn |
| Dec 31, 2021 | -6.95 Mn |
| Dec 31, 2021 | -6.95 Mn |
| Sep 30, 2021 | -5.00 Mn |
| Sep 30, 2021 | -5.00 Mn |
| Jun 30, 2021 | -5.98 Mn |
| Jun 30, 2021 | -5.98 Mn |
| Mar 31, 2021 | -6.38 Mn |
| Mar 31, 2021 | -6.38 Mn |
| Dec 31, 2020 | -5.41 Mn |
| Dec 31, 2020 | -5.41 Mn |
| Sep 30, 2020 | -8.21 Mn |
| Sep 30, 2020 | -8.21 Mn |
| Jun 30, 2020 | -2.60 Mn |
| Jun 30, 2020 | -2.60 Mn |
| Mar 31, 2020 | -4.37 Mn |
| Mar 31, 2020 | -4.37 Mn |
| Dec 31, 2019 | -3.76 Mn |
| Dec 31, 2019 | -3.76 Mn |
| Sep 30, 2019 | -1.48 Mn |
| Sep 30, 2019 | -1.48 Mn |
| Jun 30, 2019 | -2.33 Mn |
| Jun 30, 2019 | -2.33 Mn |
| Mar 31, 2019 | -3.28 Mn |
| Mar 31, 2019 | -3.28 Mn |
| Dec 31, 2018 | -2.01 Mn |
| Dec 31, 2018 | -2.01 Mn |
| Sep 30, 2018 | -1.58 Mn |
| Sep 30, 2018 | -1.58 Mn |
| Jun 30, 2018 | -3.08 Mn |
| Jun 30, 2018 | -3.08 Mn |
| Mar 31, 2018 | -3.52 Mn |
| Mar 31, 2018 | -3.52 Mn |
| Dec 31, 2017 | -3.90 Mn |
| Dec 31, 2017 | -3.90 Mn |
| Sep 30, 2017 | -3.12 Mn |
| Sep 30, 2017 | -3.12 Mn |
| Jun 30, 2017 | -5.00 Mn |
| Jun 30, 2017 | -5.00 Mn |
| Mar 31, 2017 | -3.86 Mn |
| Mar 31, 2017 | -3.86 Mn |
| Dec 31, 2016 | -4.87 Mn |
| Dec 31, 2016 | -4.87 Mn |
| Sep 30, 2016 | -3.44 Mn |
| Sep 30, 2016 | -3.44 Mn |
| Jun 30, 2016 | -4.61 Mn |
| Jun 30, 2016 | -4.61 Mn |
| Mar 31, 2016 | -3.49 Mn |
| Mar 31, 2016 | -3.49 Mn |
| Dec 31, 2015 | -4.60 Mn |
| Dec 31, 2015 | -4.60 Mn |
| Sep 30, 2015 | -5.08 Mn |
| Sep 30, 2015 | -5.08 Mn |
| Jun 30, 2015 | -2.99 Mn |
| Jun 30, 2015 | -2.99 Mn |
| Mar 31, 2015 | -4.31 Mn |
| Mar 31, 2015 | -4.31 Mn |
| Dec 31, 2014 | -3.11 Mn |
| Dec 31, 2014 | -3.11 Mn |
| Sep 30, 2014 | -3.28 Mn |
| Sep 30, 2014 | -3.28 Mn |
| Jun 30, 2014 | -2.41 Mn |
| Jun 30, 2014 | -2.41 Mn |
| Mar 31, 2014 | -3.62 Mn |
| Mar 31, 2014 | -3.62 Mn |
| Dec 31, 2013 | -1.65 Mn |
| Dec 31, 2013 | -1.65 Mn |
| Sep 30, 2013 | -1.48 Mn |
| Sep 30, 2013 | -1.48 Mn |
| Jun 30, 2013 | -1.93 Mn |
| Jun 30, 2013 | -1.93 Mn |
| Mar 31, 2013 | -2.42 Mn |
| Mar 31, 2013 | -2.42 Mn |
| Dec 31, 2012 | -1.75 Mn |
| Dec 31, 2012 | -1.75 Mn |
| Sep 30, 2012 | -2.08 Mn |
| Sep 30, 2012 | -2.08 Mn |
| Jun 30, 2012 | -2.18 Mn |
| Jun 30, 2012 | -2.18 Mn |
| Mar 31, 2012 | -1.49 Mn |
| Mar 31, 2012 | -1.49 Mn |
| Dec 31, 2011 | -1.54 Mn |
| Dec 31, 2011 | -1.54 Mn |
| Sep 30, 2011 | -1.25 Mn |
| Sep 30, 2011 | -1.25 Mn |
| Jun 30, 2011 | -1.52 Mn |
| Jun 30, 2011 | -1.52 Mn |
| Mar 31, 2011 | -1.37 Mn |
| Mar 31, 2011 | -1.37 Mn |
| Dec 31, 2010 | -583,000.00 |
| Dec 31, 2010 | -583,000.00 |
| Sep 30, 2010 | -827,000.00 |
| Sep 30, 2010 | -827,000.00 |